KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Merck (MRK) Research & Development (2016 - 2025)

Merck (MRK) has disclosed Research & Development for 17 consecutive years, with $150.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 96.73% to $150.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.1 billion, a 32.81% decrease, with the full-year FY2025 number at $15.8 billion, down 11.98% from a year prior.
  • Research & Development was $150.0 million for Q4 2025 at Merck, down from $4.2 billion in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $13.3 billion in Q2 2023 to a low of $150.0 million in Q4 2025.
  • A 5-year average of $4.2 billion and a median of $4.0 billion in 2024 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 376.09% in 2023, then crashed 96.73% in 2025.
  • Merck's Research & Development stood at $2.4 billion in 2021, then surged by 54.46% to $3.8 billion in 2022, then skyrocketed by 45.7% to $5.5 billion in 2023, then dropped by 16.65% to $4.6 billion in 2024, then plummeted by 96.73% to $150.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRK's Research & Development are $150.0 million (Q4 2025), $4.2 billion (Q3 2025), and $4.0 billion (Q2 2025).